

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/687,174	
	Filing Date	October 15, 2003	
	First Named Inventor	Jianfu J. WANG	
	Art Unit	1645	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	8 pages + 9 references	Attorney Docket Number	559312000100

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<ul style="list-style-type: none">• Form PTO-1449 (original + copy (4 pages total))• 9 References• Return receipt postcard
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	MORRISON & FOERSTER LLP (CUSTOMER NUMBER: 25226) Nicholas S. Buffinger - 39,124
Signature	
Date	March 24, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 24, 2004

Signature:

(Mei Leung)



PATENT
Docket No. 559312000100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on March 24, 2004.


Mei Leung

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jianfu J. WANG et al.

Serial No.: 10/687,174

Filing Date: October 15, 2003

For: SETS OF DIGITAL ANTIBODIES
DIRECTED AGAINST SHORT
EPITOPES, AND METHODS USING
SAME

Examiner: Not Yet Assigned

Group Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith.
The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 559312000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 24, 2004

Respectfully submitted,

By: 

Nicholas S. Buffinger
Registration No. 39,124
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5816
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 	Docket Number 559312000100	Application Number 10/687,174
	Applicant Jianfu J. WANG et al.	
	Filing Date October 15, 2003	Group Art Unit 1645
	Mailing Date March 24, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	09/27/1988	4,774,339	Haugland et al.			
	2.	07/23,1996	5,538,897	Yates, III et al.			
	3.	08/14/2001	6,274,323	Bruchez et al.			
	4.	04/02/2002	6,365,418	Wagner et al.			
	5.	06/17/2003	6,579,719	Hutchens et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	6. ✓	07/29/1999	WO 99/38185	WIPO			

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	7. ✓	Afzalpurkar, A. et al. (1997). "Identification of Epitopes of Monoclonal Antibodies to Porcine Zona Pellucida 3 β Glycoprotein, A Homologue of the Mouse/Human Sperm Receptor," <i>American Journal of Reproductive Immunology</i> 38:26-32.
	8. ✓	Åkerblom, L. et al. (1990). "Neutralizing Cross-Reactive and Non-Neutralizing Monoclonal Antibodies to HIV-1 gp120," <i>AIDS</i> 4:953-960.
	9. ✓	Demangel, C. et al. (2000). "Combining Phage Display and Molecular Modeling to Map the Epitope of a Neutralizing Antitoxin and Antibody," <i>Eur. J. Biochem</i> 267:2345-2353.
	10. ✓	Hollborn, M. et al. (1999). "Epitope Mapping of a Monoclonal Antibody Directed Against the α -Subunit of Phosphofructokinase-1 From <i>Saccharomyces Cerevisiae</i> By screening Phage Display Libraries," <i>Journal of Molecular Recognition</i> 12:33-37.
	11. ✓	Malorny, B. et al (1998). "Sequence Diversity, Predicted Two-Dimensional Protein Structure, and Epitope Mapping of Neisserial Opa Proteins," <i>Journal of Bacteriology</i> 180(5):1323-1330.
	12. ✓	Morelli, G. et al. (1997). "Clonal Descent and Microevolution of <i>Neisseria Meningitidis</i> During 30 Years of Epidemic Spread," <i>Mol. Microbiol.</i> 25(6):1047-1064.
	13. ✓	Nagasaki, H. et al. (1999). "Epitope Analysis of A Prostate-Specific Antigen (PSA) C-Terminal - Specific Monoclonal Antibody and New Aspects for the 2 Discrepancy Between Equimolar and

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 559312000100	Application Number 10/687,174
 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Jianfu J. WANG et al.	
		Filing Date October 15, 2003	Group Art Unit 1645
		Mailing Date March 24, 2004	
		Skewed PSA Assays," <i>Clin. Chem.</i> 45(4):486-496.	
	14.	Zheng, X et al. (1996). "Epitope Mapping of the Variable Repetitive Region Within the MB Antigen of <i>Ureaplasma Urealyticum</i> ," <i>Clinical and Diagnostic Laboratory Immunology</i> 3(6):774-778.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			